Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Summary

This study is being done to examine the influence of Tiotropium (good or bad) on heart function at rest and during exercise in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start

2006-10

Primary completion

2008-08

Completion

2008-08

Outcome

Missed primary endpoint

registry MEAN Tiotropium: 5.34 (Standard Deviation 1.39) L/min/m^2 MEAN Placebo: 6.70 (Standard Deviation 1.66) L/min/m^2 NCT00578968 ↗

registry analysis (superiority or other test); Tiotropium vs Placebo; p = 0.04; ANOVA NCT00578968 ↗

registry MEAN Tiotropium: 44.62 (Standard Deviation 9.0) mL/m^2 MEAN Placebo: 50.06 (Standard Deviation 12.49) mL/m^2 NCT00578968 ↗

registry analysis (superiority or other test); Tiotropium vs Placebo; p = 0.19; ANOVA NCT00578968 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tiotropium	Other / unclassified	18 ug	Inhaled

Indications